EPICS: Global Perspectives in SCLC (Region 2)

Latest therapeutic developments in SCLC treatment and implications on individualized clinical decision-making. How will emerging data shape future treatment paradigms?

August 17, 2022


Nagashree Seetharamu, MD, MBBS

Donald and Barbara Zucker School of Medicine, Hempstead, NY, USA

Faculty Members

Millie Das, MD
Stanford Cancer Center, Stanford, CA, USA

Sonam Puri, MD
University of Utah, Salt Lake City, UT, USA

Asrar Alahmadi, MBBS
Ohio State University Comprehensive Cancer Center, Columbus, OH, USA

Janakiraman Subramanian, MD
Inova Schar Cancer Institute, Fairfax, VA, USA

Isabel Preeshagul, MD, MS, DO
Memorial Sloan Kettering Cancer Center, New York, NY, USA

Roy Herbst, MD, PhD
Yale Cancer Center, New Haven, CT, USA

Mark Socinski, MD
AdventHealth Cancer Institute, Orlando, FL, USA

Sample Report

Start discovering the insights

View Report


  • Standards of Care Across the SCLC Treatment Continuum
  • Biomarkers in SCLC
  • Recent Progress and Emerging Therapies in Second Line and Beyond

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.